Drugs / AD-1151
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07385235 | Jan → Mar 2026 overdue | gastric ulcer | Addpharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06902818 | Mar → Apr 2025 | gastric ulcer | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-1151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07385235 ↗ |
| Known as | Revaprazan sulfate | “Period 1 : Reference Drug(Rebanex Tab), Period 2 : Test Drug(Revaprazan sulfate) Single-dose oral administration of AD-115A (200 mg tablet) in Period 1, followed by...” NCT07385235 ↗ |
| Route | Oral | “AD-115A , AD-1151 Oral Tablet” NCT06902818 ↗ |